<?xml version='1.0' encoding='utf-8'?>
<document id="21386025"><sentence text="Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens." /><sentence text="The Department of Health and Human Services (DHHS) HIV treatment guidelines recommend that antiretroviral regimens for treatment-naÃ¯ve individuals include at least 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus either (1) a nonnucleoside reverse transcriptase inhibitor (NNRTI), (2) a protease inhibitor (PI), or (3) raltegravir, an integrase strand transfer inhibitor" /><sentence text=" Differences in drug-drug interaction potential may represent an important differentiating feature when choosing between these regimen types" /><sentence text="" /><sentence text="To identify risk factors for clinically significant drug-drug interactions (CSDDIs) among patients on NNRTI-, PI-, and raltegravir-based antiretroviral regimens; compare CSDDI risks between these regimen types; and develop a clinical prediction tool for antiretroviral CSDDIs" /><sentence text="" /><sentence text="In this cross-sectional study, outpatient medical records from the HIV clinic at Albany Medical Center Hospital were randomly selected to review patients' current antiretroviral regimens" /><sentence text=" Patients treated with NNRTI-, PI-, or raltegravir-based regimens were included"><entity charOffset="39-50" id="DDI-PubMed.21386025.s8.e0" text="raltegravir" /></sentence><sentence text=" Drug therapies were analyzed for interactions using Lexi-Comp drug interaction software" /><sentence text=" The CSDDIs were defined as either (1) a drug combination that is contraindicated or accompanied by strong precautions per DHHS antiretroviral guidelines or (2) a drug combination that necessitates a medication dose adjustment" /><sentence text="" /><sentence text="Of the 500 patient records screened, 229 were included" /><sentence text=" Baseline characteristics were similar between regimen groups, with the exception of comorbidities" /><sentence text=" In multivariate analyses, variables independently associated with CSDDIs were use of &gt;5 non-antiretroviral medications (prevalence ratio [PR] 1" /><sentence text="86; 95% CI 1" /><sentence text="31 to 2" /><sentence text="64; p&lt;0" /><sentence text="001) and regimen type (NNRTI: PR 2" /><sentence text="48, PI: PR 4" /><sentence text="96, and raltegravir [referent]: PR 1" /><sentence text="00; 95% CI 1" /><sentence text="79 to 3" /><sentence text="44; p&lt;0" /><sentence text="001)" /><sentence text="" /><sentence text="Use of &gt;5 non-antiretroviral medications or a non-raltegravir-based antiretroviral regimen increased the risk of a CSDDI" /><sentence text=" Our findings help clarify drug interaction risks among NNRTI-, PI-, and raltegravir-based regimen types that should be considered when prescribing antiretroviral therapy"><entity charOffset="56-62" id="DDI-PubMed.21386025.s27.e0" text="NNRTI-" /><entity charOffset="73-84" id="DDI-PubMed.21386025.s27.e1" text="raltegravir" /><pair ddi="false" e1="DDI-PubMed.21386025.s27.e0" e2="DDI-PubMed.21386025.s27.e0" /><pair ddi="false" e1="DDI-PubMed.21386025.s27.e0" e2="DDI-PubMed.21386025.s27.e1" /></sentence><sentence text="" /></document>